Posters at the American Association for Cancer Research (AACR) Annual Meeting 2019 Mar 31 from 1:00 PM EDT to Apr 3, 2019 Supporting Materials Tumor-antigen 5T4-dependent Activation of the CD137 Costimulatory Pathway by Bispecific 5T4 x CD137 TRIDENT™ Molecules 2.8 MB Selection of a Bispecific Trivalent HER2 x CD137 TRIDENT™ Format Providing Optimal Tumor-anchored Immune Co-stimulation 974.8 KB Margetuximab Mediates Greater Fc-dependent Anti-tumor Activities than Trastuzumab or Pertuzumab In Vitro 1.3 MB IMGC936, a first in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity 282.9 KB PharmacodynamicCorrelates in a Phase 1 Study of INCMGA00012, a PD-1 Antagonistic Monoclonal Antibody 974.6 KB Assessment of Flat Dosing Strategy for INCMGA00012 in Patients With Advanced Tumors 1.8 MB
Tumor-antigen 5T4-dependent Activation of the CD137 Costimulatory Pathway by Bispecific 5T4 x CD137 TRIDENT™ Molecules 2.8 MB
Selection of a Bispecific Trivalent HER2 x CD137 TRIDENT™ Format Providing Optimal Tumor-anchored Immune Co-stimulation 974.8 KB
Margetuximab Mediates Greater Fc-dependent Anti-tumor Activities than Trastuzumab or Pertuzumab In Vitro 1.3 MB
IMGC936, a first in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity 282.9 KB
PharmacodynamicCorrelates in a Phase 1 Study of INCMGA00012, a PD-1 Antagonistic Monoclonal Antibody 974.6 KB